Cardio–renal axis in HF and the potential role of SGLT2 inhibitors

This module summarises scientific evidence on the interconnected cardiorenal system and the potential role of SGLT2 inhibitors in improving outcomes for patients with cardiorenal disease.

Cardio–renal axis in HF and the potential role of SGLT2 inhibitors
Rate this content
  • Cardio–renal axis in HF and the potential role of SGLT2 inhibitors
  • Cardio–renal axis in HF and the potential role of SGLT2 inhibitors
  • Stages of CKD are defined according to GFR and degree of albuminuria
  • Definition of worsening renal function (WRF) in HF
  • CKD is almost four-times more prevalent in patients with chronic HF compared with the general population
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go